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Abstract 
Brain-derived neurotrophic factor (BDNF) plays an important role in nervous system development and function and it 
is well established that BDNF is involved in the pathogenesis of a wide range of psychiatric disorders. Recently, numer-
ous studies have associated the DNA methylation level of BDNF promoters with certain psychiatric phenotypes. In this 
review, we summarize data from current literature as well as from our own analysis with respect to the correlation of 
BDNF methylation changes with psychiatric disorders and address questions about whether DNA methylation related 
to the BDNF can be useful as biomarker for specific neuropsychiatric disorders.
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Background
Brain-derived neurotrophic factor (BDNF) is a mem-
ber of the neurotrophin family which plays an impor-
tant role in neural differentiation, survival of nerve cells, 
neurite outgrowth, and synaptic plasticity. BDNF has 
been shown to regulate the development, plasticity and 
survival of dopaminergic, cholinergic and serotonergic 
neurons. Also, it regulates glutamatergic neurotransmit-
ter release and promotes the development of GABAergic 
neurons. BDNF is widely expressed throughout the mam-
malian brain, including the cerebral cortex, hippocam-
pus, basal forebrain, striatum, hypothalamus, brainstem, 
limbic structures and cerebellum [1]. This makes BDNF 
a key factor in learning and memory, reward-related pro-
cesses, cognitive function and circuit formation.
The human BDNF has a complex gene structure, con-
sisting of 11 exons (I–V, Vh, VI-VIII, VIIIh, IX), 9 of which 
(exon I–VII, IX) contain functional promoters. Exons II, 
III, IV, V, Vh, VI, and VIIIh do not have a translation start 
site so translation of these exons starts from the ATG of 
exon IX. All BDNF mRNAs contain the sequence for the 
pro-BDNF protein, encoded by exon IX. The use of trans-
lation start sites in exons I, VII, and VIII can lead to the 
pre-proBDNF proteins with longer N-termini. Alternative 
splice sites are situated in exons II, V, VI and in exon IX. 
In addition exon IX contains two alternative polyadenyla-
tion sites [2]. The use of different splice sites leads to the 
formation of numerous BDNF transcripts variants that 
determine a tissue-specific BDNF expression regulation 
as well as the regulation in responses to environmental 
stimuli and signaling events [2, 3]. mRNAs transcribed 
from the non-protein-coding antiBDNF gene and forming 
duplexes with BDNF mRNAs may play an important role 
in the regulation of BDNF expression [2]. Additionally, 
BDNF expression is regulated at the posttranscriptional 
level by enzymatic cleavage of the pro-BDNF protein into 
a mature BDNF protein. Pro-BDNF and BDNF can inter-
act with two distinct transmembrane receptors, the p75 
neurotropin receptor (p75NTR) and the tropomyosin-
related kinase receptor B (TrkB). While pro-BDNF binds 
preferentially to p75NTR, inducing neuronal apoptosis 
and long-term depression, mature BDNF binds to TrkB 
and promotes a downstream signal cascade, leading to 
neuronal differentiation and survival, neurite outgrowth 
as well as synaptic plasticity [3, 4].
The BDNF protein has been extensively studied as an 
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range of psychiatric disorders, such as major depression, 
schizophrenia and bipolar disorders. The use of several 
animal models have also implicated BDNF in anxiety-like 
behaviors and have shown a decreased BDNF expres-
sion in response to different types of stressors [5, 6]. A 
Val66Met polymorphism (rs6265) of BDNF has been 
associated with different psychiatric conditions. This 
polymorphism is related to intracellular traffic, synaptic 
location, secretion of BDNF as well as poorer working 
memory performance, reduced cerebellar and hippocam-
pal volumes, and cognitive ability [7, 8]. The polymor-
phism has been demonstrated to modulate a range of 
clinical features in schizophrenia patients. Higher fre-
quency of the Met allele has also been associated with 
depression, anxiety, anorexia, bulimia nervosa and sui-
cidal behavior [9, 10].
Numerous studies have addressed the association 
between psychological disturbances and levels of BDNF 
protein in serum or plasma. There are several sources of 
BDNF in blood: BDNF might be secreted by platelets, 
immune and vascular endothelial cells [11, 12]. BDNF 
is also able to overcome the blood–brain barrier [13]. 
With the correlations reported between BDNF levels in 
the brain and blood, altered BDNF levels has been estab-
lished as characteristic for several psychological disor-
ders. Low serum BDNF protein levels have been found in 
patients with depression, schizophrenia, anxiety and bor-
derline personality disorder [14–17]. While certain treat-
ments with antidepressants increased levels of BDNF in 
serum [14], a pre-treated level of BDNF has been shown 
to possibly predict the response to antidepressant treat-
ment and has been correlated with depression rating 
improvements during therapy [18]. However, such clini-
cal parameters as age of onset, the severity of symptoms 
as well as clinical effectiveness of the treatment were 
not reflected by BDNF levels in blood [14]. Additionally, 
proBDNF and the mature BDNF form cannot be dis-
criminated by measurement in blood although they affect 
neuronal cells differently [16]. Since alterations of BDNF 
levels in blood associate with several psychological disor-
ders, it cannot be considered as a specific biomarker for 
certain disease.
Epigenetic alterations as DNA methylation, histone 
modifications and non-coding RNAs are considered to 
be strongly associated with pathogenesis of psychiat-
ric disorders (reviewed in [19, 20]) with a large number 
of studies having examined the association between the 
BDNF methylation level and certain psychological diag-
noses. Epigenetic mechanisms have been shown to be 
very important for BDNF expression regulation [3, 4, 21, 
22]. DNA methylation-related chromatin remodeling of 
BDNF regulatory regions may play critical roles in regu-
lating gene transcription in response to neuronal activity 
[23, 24]. Epigenetic modifications, on the other hand, 
may potentially provide robust and stable biomarkers of 
disease activity. In this review, we have summarized the 
information about individual CpG sites and CpG regions 
previously tested in BDNF promoters and shown to be 
connected to psychiatric disorders. Using open access 
databases, we have analyzed the DNA methylation level 
of BDNF promoters in brain samples of individuals with 
psychiatric disorders. This review addresses the ques-
tion of whether BDNF methylation changes might be 
regarded as suitable biomarkers of a specific disorder.
A role of DNA methylation in gene expression
Epigenetic changes are gene expression and phenotype 
alterations heritable through cell division that are not 
caused by modifications in DNA sequences [25]. The 
main epigenetic mechanisms include DNA methyla-
tion, histone modifications and non-coding RNAs. DNA 
methylation is the first described and the most studied 
epigenetic modification [26]. Mammalian DNA meth-
ylation occurs predominantly in the nucleotide sequence 
5′CpG3′. There are about 28 million CpG sites in the hap-
loid human genome. CpG islands are defined as those 
sequences that have a length greater than 200 bp, a CpG 
content of at least 50 % and a CpG frequency greater than 
0.6 of observed number to the expected number of CpGs 
[27]. The promoter regions of 60–70  % of all human 
genes contain CpG islands [26]. Traditionally high den-
sity CpG islands have been considered mostly hypometh-
ylated [27, 28], however more recent studies have shown 
that dense CpG islands, depending on cell type, might 
be predominately hypermethylated [29]. A DNA meth-
ylation pattern is established and maintained by DNA 
methyltransferases (DNMT) namely de novo DNMT3A 
and DNMT3B and the maintenance DNMT1 [26]. DNA 
methylation affects gene expression, involving multiple 
mechanisms. Gene expression silencing is mediated by 
methylated DNA by attracting transcriptionally repres-
sive methyl-CpG-binding proteins (MBPs). In turn, these 
proteins recruit histone deacytelases (HDACs) and chro-
matin-remodeling complexes, such as an NCoR-SMRT 
complex (nuclear receptor corepressor and silencing 
mediator for retinoid and thyroid hormone receptors), a 
NuRD (Nucleosome Remodeling Deacetylase) complex, 
which results in gene repression. The DNA methylation 
of a gene enhancer may also lead to gene repression. On 
the other hand, unmethylated CpG sites are bound by 
methyl-sensitive transcription factors, CXXC domain-
containing activator complexes, thereby contributing to 
gene expression (reviewed in [30]). Unmethylated CpG 
sites might also serve as transcriptional factors “land-
ing lights”, marking gene promoter regions which dis-
tinguishes them from the transcriptionally irrelevant 
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intergenic chromatin [27]. Gene body DNA methylation 
may have a positive influence on gene transcription [31] 
and intragenic DNA methylation may affect alternative 
gene splicing [32]. Other interesting findings are the cor-
relation between the density of gene-body DNA meth-
ylation and replication timing [30], and the influence of 
5′UTR and 3′UTR DNA methylation on the elongation 
and termination of transcription [33].
Initially DNA methylation has been associated with 
prevention of particular gene expression. However, 
recent studies have introduced a more complicated 
impact of DNA methylation on gene expression regula-
tion with several studies having identified a poor correla-
tion between methylation levels of some genes and their 
expression level [27]. Differential DNA methylation of 
CpG islands associated with repressed genes has been 
found between somatic cells [27] which might imply sto-
chastic DNA methylation of repressed genes. A few stud-
ies indicated that binding of transcription factors may 
precede DNA methylation changes in the enhancer, sug-
gesting an inactive role of DNA methylation in enhancer 
activity [34]. Thus, DNA methylation is a complex epi-
genetic modification, which does not always determine 
gene expression activity. Several studies align with the 
idea that DNA methylation changes might be triggered 
by an antisense transcription, changes in histone modifi-
cation and chromatin protein activity and thus might be 
a consequence rather than a reason for gene regulation 
[34–36].
Dynamic changes in DNA methylation are considered 
important mechanisms in the developmental regulation 
of gene expression. Embryonic stem cells are pluripotent 
and characterized by hypomethylation of CpG islands. 
During differentiation, genes essential for cell specifica-
tion remain unmethylated while opposite genes, specific 
for other cell line development, are kept methylated. 
According to this notion, somatic cells demonstrate dif-
ferent DNA methylation patterns of a number of genes. A 
genome-wide analysis, comparing the DNA methylation 
profile across brain and blood, reveals highly tissue-spe-
cific differences in DNA methylation between different 
cortical regions, cerebellum and blood. It has also been 
shown that tissue-specific differentially methylated 
regions (TS-DMR) across the cerebellum and frontal cor-
tex are associated with stable gene expression differences 
[37]. One of most interesting findings was an over-rep-
resentation of intragenic CpG islands and an under-rep-
resentation of promoter-associated CpG islands among 
TS-DMR. Low density CpG promoters were charac-
terized by widespread tissue-specific DNA methyla-
tion across brain regions and blood, in comparison with 
CpG-rich promoters [37]. An intriguing recent study 
has also demonstrated a significant underrepresentation 
of promoter regions and an overrepresentation of CpG 
shores and shelves, gene bodies, as well as underrep-
resentation of CpG-rich promoters among fetal brain 
DMRs [38]. Another whole genome DNA methylation 
study has shown that similar pathways are affected in the 
brain and blood of Parkinson’s patients. Differently meth-
ylated regions between the blood and brain have been 
predominately presented in high-methylation fractions 
which are associated with gene bodies and intragenic 
regions [39].
5-hydroxymethylcytosine (5hmC), derived from oxi-
dation of 5-methylcytosine (5mC) by the Ten-Eleven 
Translocation (TET) enzymes, is now considered a new 
epigenetic DNA modification with relevant roles in regu-
lating DNA demethylation and transcription. 5hmC is 
generally associated with transcribed genes promoters 
and bodies, positively correlated with transcription levels 
and detected in the mammalian genome in all cell types, 
with the highest content present in the brain [40].
The role of DNA methylation in the regulation of 
Bdnf expression was actively investigated by Martino-
wich and colleagues [23]. The authors found a three-
four times higher level of the Bdnf exon IV transcript in 
Dmnt1 mutant mice in comparison with controls. It was 
also demonstrated that the activation of Bdnf transcrip-
tion is regulated by neuronal activity. Enhanced tran-
scription of the Bdnf exon IV promoter was observed 
in mouse embryonic cortical cells treated with 50  mM 
KCL, which is known to simulate neuronal activity by 
activation of voltage-sensitive calcium channels lead-
ing to calcium influx and membrane depolarization. 
More importantly, the authors identified that the region 
upstream of the Bdnf promoter IV transcriptional start 
site contains Ca2+-responsive elements, namely the cal-
cium-responsive element 1 (CaRE1), an upstream stimu-
latory factor-binding site (E-box) and a cyclic adenosine 
monophosphate (cAMP) response element (CRE), which 
overlap with several CpG sites. A site-specific DNA 
methylation in combination with a luciferase activ-
ity test showed that DNA methylation of some of these 
CpG sites can significantly inhibit the Bdnf promoter IV 
activity induced previously by membrane depolariza-
tion. Further experiments showed that the methylation 
level of several CpG sites in the Bdnf exon IV was signifi-
cantly lower in KCl-treated culture of mouse E14 corti-
cal cells compared with control culture. This confirms 
that the methylation level of the Bdnf promoter IV can 
be changed upon depolarization. Subsequent chroma-
tin immunoprecipitation analysis revealed that methyl-
CpG-binding protein MeCP2 (transcription repressor) is 
more tightly associated with methylated DNA within the 
Bdnf exon IV than CRE-binding protein (transcription 
activator). Coimmunoprecipitation assay demonstrated 
Page 4 of 14Zheleznyakova et al. Behav Brain Funct  (2016) 12:17 
that the histone deacytelase HDAC1 and corepres-
sor mSin3A also associated with the Bdnf promoter. 
All three proteins dissociated from the promoter upon 
membrane depolarization suggesting that Bdnf expres-
sion activation requires the dissociation of the MeCP2-
HDAC-mSin3A repression complex. All together, these 
findings indicated that Bdnf expression level is deter-
mined by the DNA methylation pattern and chroma-
tin modifications which, in turn, can be regulated by 
membrane depolarization. In a latter study, the regula-
tion of human BDNF transcription by membrane depo-
larization was confirmed [41]. The authors indicated 
that neuronal activity-regulated transcription of human 
BDNF promoter I depends primarily on the novel asym-
metric E-box-like element, PasRE (basic helix-loop-helix 
(bHLH)-PAS transcription factor response element), 
which is bound by the bHLH-PAS transcription factors 
ARNT2 (aryl hydrocarbon receptor nuclear translocator 
2) and NPAS4 (neuronal PAS domain protein 4). While 
neuronal activity-regulated transcription of the BDNF 
promoter IV is regulated predominately by CRE, PasRE 
elements and the upstream stimulatory factor binding 
element (UBE). The CRE and PasRE elements overlap 
with CpG sites (Fig. 1), however a separate study is nec-
essary to investigate if DNA methylation of these CpG 
sites can influence transcription of the BDNF promoters 
following membrane depolarization.
Several studies in rats have demonstrated that stress-
ful environment conditions, such as an early-life adverse 
experience or maltreatment, may induce long-lasting 
changes in the methylation level of the Bdnf promoter 
IV which is associated with the lower Bdnf expression 
level in prefrontal cortex. Moreover, the offspring derived 
from maltreated-females showed hypermethylation of 
the Bdnf in the prefrontal cortex and hippocampus, sug-
gesting that DNA methylation modifications might be 
inherited across generations [42, 43].
DNA methylation of BDNF in psychiatric disorders
DNA methylation alterations of BDNF, in connection to 
various psychiatric disorders, have been extensively stud-
ied in last several years (Table 1). Firstly, BDNF was stud-
ied by applying the enrichment microarray analysis; Mill 
and colleagues [44] tested the methylation level of sev-
eral BDNF regions. They did not reveal any difference in 
the methylation level in patients with schizophrenia and 
bipolar disorders in comparison with controls. However, 
they identified an influence of rs6265 genotype, situated 
in exon IX on the methylation level of the surrounding 
region. Depending on the allele (C or T) of the rs6265, 
an additional CpG site can emerge in the region. CC (Val 
homozygotes) genotype carriers demonstrated a signifi-
cant increase in methylation levels of four nearby CpG 
sites in comparison with CT and TT (Met homozygotes) 
genotype carriers. This is especially interesting, as sev-
eral studies have shown the opposite effect of the Val/Val 
and Met/Met genotype on the schizophrenic and non-
psychotic psychiatric disease phenotype [9]. In the recent 
study of Chagnon and colleagues, a significantly higher 
methylation level of one BDNF region (exon VI, 3 CpG 
sites) was observed in older women with anxiety and/or 
depression compared with controls [45]. This difference 
was more pronounced in CT genotype carriers of rs6265 
in comparison with the CC genotype carriers. TT car-
riers were not found among both patients and controls. 
The higher DNA methylation in women with anxiety/
depression compared with healthy controls was con-
firmed in a second small CT genotype carriers’ cohort 
(eight subjects). No difference was detected for CC and 
TT carriers. A comprehensive study assessing the whole 
BDNF methylation levels in a large cohort of CC, CT and 
TT carriers will be necessary to elucidate the impact of 
rs6265 on the methylation level of distal BDNF regions.
Keller and colleagues were the first to investigate the 
BDNF DNA methylation changes in suicide victims in 
comparison with controls [46]. Using bisulfite pyrose-
quencing and direct bisulfite sequencing, EpiTYPER as a 
confirmation analyses, these authors analyzed the meth-
ylation levels of CpG sites at BDNF promoter/exon IV 
in the Wernicke area of the brain. A significant increase 
of the average methylation level of 4 CpG sites located 
downstream of TSS (+10, +16, +25, +28) (Fig. 1b) and 
methylation levels of two separate CpG sites (+10, +25) 
was found in suicide completers. Moreover, they also 
indicated an association between the average methyla-
tion level of these 4 CpG sites and the BDNF transcript 
IV levels.
Fuchikami and colleagues were the first to examine the 
possibility of DNA methylation changes as a biomarker 
of major depression. Applying the EpiTYPER technique, 
these authors determined the methylation level of two 
CpG islands associated with promoter I and promoter 
IV of BDNF in major depressive disorder (MDD) patients 
in comparison with healthy individuals. The methyla-
tion levels of 29 out of 35 CpG sites inside of promoter 
I (Fig.  1a) were significantly different between patients 
and controls, although different CpG sites demonstrated 
multidirectional methylation changes. 21 CpG sites 
showed increased methylation levels in controls, while 
the other 8 CpG sites showed increased methylation lev-
els in depression patients [47].
In a study of major depressed patients with suicidal 
behavior, higher BDNF promoter VI methylation lev-
els were found to be strongly associated with a previ-
ous history of suicidal attempts, suicidal ideation and 
less improvement during antidepressant treatment, 
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independent of the antidepressant type [48]. As BDNF 
methylation status was not measured after the treatment 
in this study, it is not possible to conclude if treatment 
outcomes might be reflected by DNA methylation status. 
In two subsequent studies, authors found a significant 
association between the BDNF promoter VI methyla-
tion levels and late-life depression [49] as well as depres-
sion related to breast cancer [50]. It is worth mentioning, 
that both studies did not reveal any association between 
the methylation level of the analyzed region and rs6265 
genotype.
Kleimann and colleagues, for the first time, examined 
an effect of electroconvulsive therapy (ECT) on DNA 
methylation of BDNF [51] in treatment-resistant major 
depressive patients. The difference in the methylation 
level of BDNF promoter I was presented between remit-
ters/responders and non-remitters/non-responders over 
the whole series of ECT treatment. It is difficult to say if 
the found difference was conditioned by only ECT since 
there was no information about BDNF methylation level 
before ECT and most patients were previously treated by 
antidepressants and/or antipsychotics.
By means of bisulfite pyrosequencing, Igekame and 
colleagues found a significant increase (about 1  %) of 
the methylation level of one CpG site in the promoter I 
of BDNF in schizophrenia patients compared with con-
trols [52] (Fig. 1a). Only in the male group of patients 
the additional CpG site was approximately 2  % higher 
methylated. It should be noted that the differences were 
not significant after multiple corrections and the sam-
ple size is not large enough to estimate a methylation 
level difference as low as 1–2 %. Authors did not reveal 
any difference in the methylation level of BDNF pro-
moter IV.
On the contrary, Kordi-Tamandani and colleagues 
revealed that the methylated allele frequency of the 
BDNF promoter IV was lower in the schizophrenia 
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Fig. 1 The positions of CpG sites analyzed in BDNF promoter I/exon I (a) and promoter IV/exon IV (b) in various studies. The CpG sites that are 
significantly differently methylated between cases and controls are marked yellow. The CpG sites, which are part of the significantly different meth-
ylated regions, are marked green. TSS is indicated by +1. Additional CpG sites inside of promoter I are highlighted red. The positions of the CpG sites 
on Infinium 450 K platform are shown. CRE, PasRE, UBE—cis-elements regulating neuronal activity-dependent transcription of BDNF promoters
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data, the relative expression level of BDNF was signifi-
cantly higher in schizophrenia patients than in controls 
[53].
In the study of D’Addario, a 7 % increase of DNA meth-
ylation at the region of BDNF promoter I (Fig.  1a) was 
observed in bipolar disorder (BD) II patients, but not BD 
I, compared with controls [54]. This was in correlation 
with the significantly decreased BDNF expression in BD 
II subjects. It should be taken in account that these data 
do not reflect the initial DNA methylation levels of BD 
patients, since part of the patients enrolled in the study 
were maintained on a diverse antidepressant treatment 
for at least 1  month. Interestingly, the authors showed, 
that BD patients on antidepressant treatment revealed 
a higher BDNF methylation level compared with anti-
depressants-free patients. However, the patients treated 
by valproate and lithium demonstrated a significantly 
decreased BDNF methylation level, in comparison with 
the control level.
In the subsequent study, these authors extended the 
BDNF promoter I methylation level analysis to the 
group of patients with major depression on stable phar-
macologic treatment in comparison with healthy indi-
viduals [55]. In concordance with the previous study, 
a significantly increased methylation level of the ana-
lyzed region inside of BDNF promoter I was observed in 
MDD patients together with a significant reduction of 
BDNF expression. These authors also showed that MDD 
patients treated only by antidepressant drugs (i.e., selec-
tive serotonin and selective norepinephrine reuptake 
inhibitors) had a 10  % higher methylation level of the 
BDNF promoter in comparison with patients treated by 
combinatory therapy of antidepressants and mood stabi-
lizers [55].
However, in a further study which was performed on 
a larger cohort of MDD, BD I and BD II patients, these 
authors were not able to show the effect of mood sta-
bilizers on DNA methylation [56]. Patients treated by 
lithium and valproate tend to demonstrate BDNF methyl-
ation levels close to controls in comparison with patients 
treated by other antidepressant agents such as selective 
serotonin reuptake inhibitors, serotonin norepinephrine 
reuptake inhibitors and atypical antipsychotics. MDD 
subjects and BD II patients showed a significantly higher 
methylation level of the analyzed region in comparison 
with BD I subjects [56].
In the absence of an initial DNA methylation status 
for the patients, the results of these studies are difficult 
to interpret. It is not possible to discriminate if these 
described changes in the methylation level among differ-
ent diagnostic groups are associated with disease status 
or whether they are connected with various pharmaco-
logical treatments. It was noted that BD I patients were 
mostly treated by mood stabilizers, while inside of the BD 
II and MDD groups, patients obtained a different therapy 
[56]. Thus, the BDNF promoter methylation analysis in 
drug-naive MDD, BD patients is necessary in order to 
make a reliable conclusion about whether this parameter 
might be used as biomarker.
Interesting results have been obtained in a study by 
Tadic and colleagues where the correlation between 
DNA methylation of BDNF promoter IV (Fig.  1b) in 
major depressive patients and antidepressant treatment 
response was assessed [57]. Of the 12 analyzed CpG 
sites, the methylation level of one CpG site was about 
2  % lower in non-responders compared to responders. 
Following this, in vitro experiments showed a decreased 
luciferase expression of a vector containing an unmeth-
ylated fragment of BDNF promoter IV, in response to 
both SSRI and the SNRI treatment. These findings were 
connected with the ability of antidepressants to phospho-
rylate MeCP2, which leads to its dissociation from a pro-
moter and consequently to the activation of expression. 
Moreover, these authors suggested that the DNA meth-
ylation status may play a significant role in the binding 
of MeCP2 to the promoter region and described that the 
mechanism of antidepressant action on BDNF can only 
be active in carriers of methylated allele at the specific 
CpG site. However, it is difficult to say that this conclu-
sion was supported by experimental in vivo data, as both 
responders and non-responders demonstrated a strongly 
hypomethylated (4–6 %) status of the analyzed region.
DNA methylation levels of the BDNF promoter I and 
promoter IV (Fig.  1) were studied in patients with bor-
derline personality disorder (BDP), whose disease phe-
notype is closely related to the depression and suicide 
phenotype. Using the high resolution melt (HRM) anal-
ysis, Perround and colleagues observed that regions in 
the BDNF promoter I and promoter IV had an almost 8 
and 18  % higher methylation level respectively for BDP 
patients [58]. Moreover, a larger number of childhood 
maltreatment was significantly associated with a higher 
methylation status of BDNF promoters (mean percent-
age at both regions). Another very interesting result of 
this study is that during the intensive dialectical behav-
ior therapy (I-DBT) non-responders showed increased 
BDNF methylation levels, while responders showed a 
decrease in BDNF methylation status, in some cases 
comparable to the methylation level of controls. This sug-
gests that BDNF methylation changes might be relevant 
for treatment response prediction. The limitation of this 
study is that most of the subjects were on antidepres-
sant treatment before I-DBT, that way the determined 
methylation level of BDP patients before treatment does 
not directly reflect a baseline methylation level of such 
patients.
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An additional study of the influence of childhood 
maternal care on BDNF methylation level was performed 
by Unternaehrer and colleagues [59]. Authors showed 
greater whole blood DNA methylation in the low versus 
high maternal care group in a CpG island situated within 
the BDNF exon VI. More importantly, authors investi-
gated differential blood cell distribution as a potential 
factor in connection with maternal care and DNA meth-
ylation of BDNF. It should be considered as an example of 
a standard experimental set up for such types of studies 
due to the blood cell specific DNA methylation pattern.
Thaler and colleagues explored DNA methylation 
changes of the BDNF promoter IV (Fig.  1b) in women 
with bulimic eating syndromes [60]. These women dis-
played increases in the methylation level at specific CpG 
sites, especially in cases when the bulimic syndromes 
were complicated by borderline personality disorder or 
history of severe childhood abuse. It is interesting that 
majority of found CpG sites were binding sites for vari-
ous transcriptional factors. As no multiple corrections 
were applied, additional studies will be required to con-
firm the obtained differences.
Open access study analysis
Material
Four databases from the ArrayExpress Archive of Func-
tional Genomics Data (http://www.ebi.ac.uk/array-
express) have been included in the analysis. Detailed 
information about each database can be found in Table 2.
Method
In the databases, the DNA methylation level was assessed 
at over 485,000 CpG sites using the Illumina Infinium 
Human Methylation450 Bead Chip. 25 probes corre-
sponding to 12 CpG sites situated in the BDNF pro-
moter I/exon I (Fig.  1a) and to 13 CpG sites situated 
in the BDNF promoter IV/exon IV were included in the 
analysis (Fig. 1b). The methylation level of each promoter 
was calculated by averaging the methylation levels of the 
corresponding CpG sites. Distribution normality for all 
variables was checked using Kolmogorov–Smirnov test. 
Because of non-Gaussian distribution, statistical compar-
isons of methylation levels between patients and controls 
were performed using the non-parametric Mann–Whit-
ney test, although in the text and in the tables values are 
presented as mean ± SEM. A Bonferroni correction was 
used to adjust for multiple comparisons. Statistical analy-
ses were performed using GraphPad Prism5 (GraphPad) 
and the statistical software R (http://www.r-project.org). 
A significance level of a = 0.05 or less was considered sig-
nificant. The statistical power analysis for the described 
studies and the open access databases was performed 
with a web browser program “Post-hoc Power Calcula-
tor” (http://clincalc.com/Stats/Power.aspx#1).
Results
According to results of previous studies both promoter 
I and IV of BDNF demonstrated strongly hypomethyl-
ated levels in all analyzed cohorts (Table 3). Frontal cor-
tex methylation levels of both promoters I and IV were 
lower in schizophrenia subjects compared to controls 
(E-GEOD-61431, E-GEOD-61380, E-GEOD-61107 data-
bases). Cerebellum methylation levels of promoter IV 
were lower in schizophrenia patients, at the same time 
cerebellum methylation levels of promoter I were simi-
lar in patients and controls. After applying multiple cor-
rections, a significant difference in the methylation level 
of BDNF promoter I (p =  0.0023, Mann–Whitney test; 
E-GEOD-61380 database,) and of BDNF promoter IV 
(p = 0.0015, Mann–Whitney test; E-GEOD-61107 data-
base) was found between schizophrenia patients and 
healthy individuals  (Table  3). However, the power anal-
ysis indicated that the E-GEOD-61380 database is not 
Table 2 Open access analyzed databases
Database Phenotype Brain region Groups Age (years: mean ± SD)
E-GEOD-61107 Schizophrenia Frontal cortex 23 SCZ: 7F, 16M 51.61 ± 21.55
24 CT: 5F, 19M 71.29 ± 9.76
E-GEOD-61380 Schizophrenia Frontal cortex 18 SCZ: 3F, 15M 45.5 ± 16.61
15 CT: 2F, 13M 42.2 ± 14.85
E-GEOD-61431 Schizophrenia Frontal cortex 20 SCZ: 9F, 11M 62.05 ± 15.87
23 CT: 6F,17M 62.04 ± 18.74
E-GEOD-61431 Schizophrenia Cerebellum 21 SCZ: 10F, 11M 61.76 ± 16.61
23 CT: 6F, 17M 61.39 ± 19.25
E-GEOD-41826 Major depression Frontal cortex: Split glial and neuronal cells 29 MDD: 15F, 14M 32 ± 15.92
29 CT: 15F, 14M 32.1 ± 16.06
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powerful enough to determine a 0.3 % methylation level 
difference.
We did not observe any difference between MDD 
patients and controls in the methylation levels of BDNF 
promoters I and IV in the frontal cortex neuronal and 
glial cells (E-GEOD-41826). We separately analyzed sev-
eral CpG sites which were determined as significantly 
differently methylated in previous studies (Fig. 1). The dif-
ference was found in the methylation level of cg14589148 
(p = 0.0147, Mann–Whitney test; E-GEOD-61380 data-
base), cg25457956 and cg10022526 (p  =  0.0396 and 
p =  0.0227, Mann–Whitney test; E-GEOD-61431 data-
base, cerebellum), however these data did not remain sig-
nificant after multiple corrections.
Discussion
The variety and complexity of psychiatric disorders is 
very high and biomarkers able to reliably differentiate 
characteristics of certain similar disorders, determine 
severity and treatment efficiency which could be very 
valuable. Taking into the consideration the inaccessibility 
of the target tissue—the brain—in psychiatric disorders, 
an ideal biomarker should be easily peripherally meas-
ured but at the same time it should reflect disease-asso-
ciated alterations in the target tissue. DNA methylation 
is a stable and heritable modification and can be reliably 
measured from a small amount of material regardless of 
the storage conditions. These remarkable characteristics 
make DNA methylation a robust biomarker of disease 
activity. Numerous cancer studies have proven that DNA 
methylation changes allow manifestations of different 
pathological stages of disease and monitoring of treat-
ment efficiency (reviewed in [61]).
At present, a growing body of data has associated 
BDNF promoters’ methylation level with development 
of various neuropsychiatric disorders. Most of the stud-
ies have analyzed different regions within promoter I 
and promoter IV. As it is demonstrated in Fig.  1a, the 
promoter I region is differently methylated in major 
depression and bipolar disorders patients in the studies 
done by D’Addario. These partly overlap with the region 
differently methylated in BPD patients of the Perroud’s 
study and with one CpG site differently methylated in 
major depression patients of the Fuchikami’s study. 
Similarly, within promoter IV, the CpG sites are differ-
ently methylated in suicide completers of Keller’s study, 
in patients with BDP and BN of the Taler’s study, and in 
major depressive patients in Tadic’s study, which partially 
overlap with the differently methylated region in BPD 
patients in Perroud’ study (Fig.  1b). These overlapping 
regions within BDNF promoter I and promoter IV may 
be of special interest as possible biomarker of psychiatric 
diseases, taking into consideration that several independ-
ent studies reported about the differences in the meth-
ylation level of these regions. Although the methylation 
levels’ alteration of these regions associated with multiple 
Table 3 Methylation levels of BDNF promoters I and IV assessed in patients from open access databases
* Significant after multiple correction
Patients Controls p value Statistical power
Mean SEM Mean SEM
Database E-GEOD-61107 (Schizophrenia, frontal cortex)
 Promoter I 0.093 0.0026 0.099 0.002 0.09
 Promoter IV 0.113 0.0028 0.126 0.003 0.0015* 90.6 %
Database E-GEOD-61380 (Schizophrenia, frontal cortex)
 Promoter I 0.105 0.0009 0.108 0.002 0.0023* 30.4 %
 Promoter IV 0.119 0.0012 0.12 0.0016 0.61
Database E-GEOD-61431 (Schizophrenia, frontal cortex)
 Promoter I 0.123 0.0016 0.128 0.0017 0.13
 Promoter IV 0.157 0.0018 0.161 0.002 0.22
Database E-GEOD-61431 (Schizophrenia, cerebellum)
 Promoter I 0.119 0.0027 0.117 0.0018 0.98
 Promoter IV 0.141 0.003 0.148 0.0029 0.0345 40 %
Database E-GEOD-41826 (MDD, frontal cortex, neurons)
 Promoter I 0.094 0.0007 0.093 0.0008 0.24
 Promoter IV 0.126 0.0009 0.125 0.001 0.39
Database E-GEOD-41826 (MDD, frontal cortex, glia)
 Promoter I 0.106 0.001 0.107 0.001 0.30
 Promoter IV 0.125 0.001 0.126 0.001 0.32
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disorders do not allow the consideration of these meth-
ylation changes as reliable biomarkers for certain psychi-
atric disturbances.
Most of the studies have been performed using periph-
eral blood cells. The main question which appears is to 
what extent DNA methylation changes in blood can 
reflect the changes in the target tissue—the brain; a 
highly tissue-specified BDNF expression implies varia-
tion of BDNF promoter methylation level in various tis-
sues. However, it has been reported that there might not 
be an exact correlation between gene DNA methylation 
and its expression level [27]. Moreover, all studies were 
concentrated on the methylation levels of BDNF promot-
ers, which are CpG rich. It is well established that differ-
ently methylated regions across the brain and blood are 
primarily located in intragenic regions and are underrep-
resented in promoter and regulatory gene regions. CpG 
rich promoters were characterized by less tissue-specific 
DNA methylation across brain regions and blood [37, 
39]. Recently, a strong correlation between the ventral 
prefrontal cortex and quadriceps for the methylation 
levels of BDNF promoter I has been found [62]. Similar 
epigenetic changes, particularly DNA methylation, in 
the brain and peripheral tissues in connection to psychi-
atric disorders might be initiated by environmental fac-
tors such as maternal stress or diet during early prenatal 
development or even have an inherited character. In the 
postnatal period, mothering behavior, early life traumas, 
environmental stressors factors and hormone dissonance 
may be responsible for the widespread epigenetic altera-
tions associated with the psychiatric phenotype [19, 42, 
43]. Keller and colleagues demonstrated that BDNF pro-
moters’ DNA methylation changes in brain are associated 
with major depression and suicide. In one of the brain 
open-access databases, we revealed a significant but 
minor (1.3 %) difference in the average methylation level 
of BDNF promoter IV in schizophrenia patients.
Most of the changes found in the BDNF methylation 
levels between patients and healthy individuals are very 
subtle. The question about whether these differences may 
initiate changes in the BDNF expression levels has been 
partly addressed in previous studies. Thus, Keller and col-
leagues indicated much lower BDNF transcript IV levels 
in samples showing 20 to 30 % methylation of 4 CpG sites 
in BDNF promoter IV compared with samples show-
ing 3 to 5 % methylation [46]. In the study of D’Addario 
and colleagues, a 9  % alteration in the BDNF promoter 
I methylation level between BDII patients and controls 
was matched with changes in the BDNF expression level 
in the blood cells [54]. It may suggest that the 9–15  % 
difference of the BDNF methylation level is functionally 
relevant and can induce changes in the BDNF transcripts 
level. In turn, Perroud and colleagues were not able 
to find any correlation between the BDNF promoters’ 
methylation and BDNF protein levels, although an 8 and 
18 % methylation level difference was found respectively 
in BDNF promoter I and promoter IV between BDP 
patients and controls [58]. The discordance, in the asso-
ciation of the BDNF protein level with the DNA meth-
ylation level, might be conditioned by other regulators 
of BDNF expression: particularly histone modifications, 
miRNAs, antiBDNF transcripts, formation of dsRNA 
duplexes with BDNF transcripts, alternative splicing, 
and posttranscriptional cleavage. Recent studies have 
introduced the idea that DNA methylation may not even 
have an active influence on gene expression, but instead 
it might reflect gene expression regulation, mediated by 
histone modifications or chromatin structure [34]. Addi-
tionally, DNA hydroxymethylation, which cannot be dis-
tinguished from DNA methylation by bisulfite treatment, 
can impact BDNF expression in a manner opposite to 
DNA methylation. Therefore, a complex analysis of sev-
eral factors determining BDNF expression is necessary to 
make the conclusion of whether the small changes in the 
BDNF methylation level may affect the BDNF expression 
changes both on transcript and protein levels.
Despite a relatively large number of studies, the use of 
the BDNF methylation level as a biomarker of psychiat-
ric disorders still needs considerable further research to 
become reality. The main reason is the lack of confirma-
tory research for each particular disease. Another factor 
is the use of a variety of techniques for methylation level 
determination (Table  1), which hampers the analysis of 
different areas within the BDNF promoters without pro-
viding a correct comparison of the results of different 
studies for the same disorder. Although, methylation-
specific real-time PCR and high resolution melt analysis 
are very sensitive methods with the ability to detect as 
little as 0.1–1  % of methylated DNA [63, 64], they can-
not provide individual CpG sites’ resolution, allowing the 
determination of the average methylation level of a whole 
region. Primer design, PCR bias or the presence of too 
many CpG sites in the analyzed region might affect the 
obtained results. The bisulfite sequencing-based tech-
niques widely applied in the studies differ also in their 
coverage and sensitivity. Direct bisulfite sequencing can 
accurately detect an intermediate difference (≥20  %) in 
methylation level while with pyrosequencing a minor dif-
ference of 5 % can be reliably detected while the resolu-
tion of cloning bisulfite sequencing is dependent on the 
number of sequenced clones [65, 66]. Furthermore, the 
inclusion of medicated and treated patients in the studies 
does not allow for specification of whether the observed 
DNA methylation changes are related to the specific 
disease phenotype or are a consequence of medical or 
psychiatric treatment. It is known that certain agents, 
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applied for psychiatric therapy, cause epigenetic modifi-
cations [67]. Insufficient attention has been paid to BDNF 
methylation level investigations in the brain. So far only 
Keller’s study and our analysis indicate a partial correla-
tion of the BDNF methylation level in the brain to the 
development of psychiatric disorders. However, we did 
not find any difference in the methylation level of the 
CpG site (cg11241206), differently methylated between 
controls and suicide completers in Keller’s study. Meas-
ured methylation levels of others CpG sites (Fig. 1), pre-
viously described as differently methylated in the studies, 
using blood cells did not show any correlation after mul-
tiple corrections. The restrictions of the method did not 
allow us to completely assess the methylation level of the 
regions analyzed in previous studies using brain samples 
as Infinium HumanMethylation450 BeadChip Kit covers 
far from all CpG sites in BDNF promoter I and IV (Fig. 1). 
A detailed analysis in the brain with a method, determin-
ing the methylation levels of all CpG sites, is required. 
Both Keller’s and our study covered only certain brain 
areas (frontal cortex, cerebellum, Wernicke area), while 
BDNF DNA methylation changes in such brain regions as 
hippocampus, nucleus accumbens, amygdala [3, 68, 69] 
may be essential for psychiatric disorders development.
Conclusions
Summing up the results of this research provides a good 
reason to believe that the methylation levels of certain 
regions within BDNF promoters can be considered as bio-
marker of specific diseases. Several independent studies 
on different patients’ cohorts with a standardized method 
for the methylation level analysis are necessary to confirm 
this suggestion. Applying the most modern approaches 
for the analysis of methylation will allow highlighting of 
the role of both DNA methylation and DNA hydroxym-
ethylation (primarily occurring in the neuronal cells) with 
regard to the development of mental illnesses. Consider-
ing the easy accessibility of blood samples, it is the DNA 
methylation level of blood cells that might be used in clin-
ical practice for accurate disease diagnosis and treatment-
efficacy monitoring. The question of DNA methylation 
discrepancy within various blood cell lines [70] and pos-
sible differences of cell composition between psychiatric 
patients and healthy individuals [71] should also be taken 
in account. Modern techniques of cell sorting and count-
ing will help to smooth over such differences. Consider-
ing the fact that most changes in DNA methylation linked 
to mental illness are fairly small in terms of percentage, 
it is necessary to use a high-resolution method that can 
reliably detect small differences. We suggest that through 
further investigations, an unequivocal answer if the BDNF 
DNA methylation level is a suitable psychiatric disorder 
biomarker may be provided.
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